Cost-effectiveness of FOLFIRINOX for first-line treatment of metastatic pancreatic cancer

Abstract

Compared with gemcitabine, first-line folfirinox significantly prolongs median os. Given the favourable cost per qaly, the improvement in clinical efficacy, and the limited available treatment options, folfirinox represents an attractive cost-effective treatment for mpc.